Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
Corvus Pharmaceuticals (NASDAQ: CRVS) has announced its participation in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference. The clinical-stage biopharmaceutical company's leadership team will engage in one-on-one meetings with investors and participate in a fireside chat presentation scheduled for March 27, 2025, at 12:00 pm ET.
The virtual presentation will be accessible through a webcast that will remain available for 90 days after the event via the company's investor relations website section.
Corvus Pharmaceuticals (NASDAQ: CRVS) ha annunciato la sua partecipazione alla 3ª Conferenza Virtuale Annuale sulle Malattie Autoimmuni e Infiammatorie di H.C. Wainwright. Il team dirigente della società biofarmaceutica in fase clinica parteciperà a incontri individuali con gli investitori e prenderà parte a una presentazione a chiacchierata informale programmata per il 27 marzo 2025, alle 12:00 ET.
La presentazione virtuale sarà accessibile tramite un webcast che rimarrà disponibile per 90 giorni dopo l'evento nella sezione del sito web dedicata alle relazioni con gli investitori della società.
Corvus Pharmaceuticals (NASDAQ: CRVS) ha anunciado su participación en la 3ª Conferencia Virtual Anual sobre Enfermedades Autoinmunitarias e Inflamatorias de H.C. Wainwright. El equipo directivo de la compañía biofarmacéutica en etapa clínica participará en reuniones individuales con inversores y participará en una presentación de charla informal programada para el 27 de marzo de 2025, a las 12:00 pm ET.
La presentación virtual será accesible a través de un webcast que estará disponible durante 90 días después del evento en la sección del sitio web de relaciones con inversores de la compañía.
Corvus Pharmaceuticals (NASDAQ: CRVS)는 H.C. Wainwright 제3회 연례 자가면역 및 염증 질환 가상 회의에 참여한다고 발표했습니다. 임상 단계의 바이오제약 회사의 경영진 팀은 투자자와 1:1 미팅을 진행하고, 2025년 3월 27일 오후 12:00 ET에 예정된 파이어사이드 채팅 발표에 참여할 예정입니다.
가상 발표는 회사의 투자자 관계 웹사이트 섹션을 통해 이벤트 후 90일 동안 이용 가능한 웹캐스트를 통해 접근할 수 있습니다.
Corvus Pharmaceuticals (NASDAQ: CRVS) a annoncé sa participation à la 3ème Conférence Virtuelle Annuelle sur les Maladies Auto-immunes et Inflammatoires de H.C. Wainwright. L'équipe dirigeante de l'entreprise biopharmaceutique en phase clinique participera à des réunions individuelles avec des investisseurs et prendra part à une présentation en discussion informelle prévue pour le 27 mars 2025 à 12h00 ET.
La présentation virtuelle sera accessible via un webinaire qui restera disponible pendant 90 jours après l'événement dans la section des relations avec les investisseurs du site web de l'entreprise.
Corvus Pharmaceuticals (NASDAQ: CRVS) hat seine Teilnahme an der 3. jährlichen virtuellen Konferenz über Autoimmun- und Entzündungserkrankungen von H.C. Wainwright bekannt gegeben. Das Führungsteam des klinischen Biopharmaunternehmens wird Einzelgespräche mit Investoren führen und an einer Fireside-Chat-Präsentation teilnehmen, die für den 27. März 2025 um 12:00 Uhr ET geplant ist.
Die virtuelle Präsentation wird über ein Webcast zugänglich sein, das 90 Tage nach der Veranstaltung über den Bereich für Investorenbeziehungen auf der Website des Unternehmens verfügbar bleibt.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and participate in a fireside chat presentation at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference, which is being held virtually. The fireside chat will be on Thursday, March 27, 2025 at 12:00 pm ET.
A webcast of the fireside chat will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website.
About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com.
INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com
MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com
FAQ
When is Corvus Pharmaceuticals (CRVS) presenting at the H.C. Wainwright Conference?
How long will the CRVS fireside chat webcast be available for viewing?
What type of meetings will CRVS conduct at the H.C. Wainwright Conference?
Where can investors access the CRVS fireside chat webcast?
